Medicine
Somatuline Depot 60 mg/0.2 mL injection
Somatuline Depot 60 mg/0.2 mL injection is a prescription medicine containing Lanreotide for subcutaneous use, marketed by Ipsen Biopharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store SOMATULINE DEPOT in the refrigerator at 2°C to 8°C (36°F to 46°F)…
Key facts
- Active ingredient (INN)
- Lanreotide
- Brand
- Somatuline Depot
- Strength
- 60 mg/0.2 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 pouch of 0.2 mL
- Marketing authorisation holder
- Ipsen Biopharmaceuticals
- Manufacturer
- Ipsen Biopharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store SOMATULINE DEPOT in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Store in the original package.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01CB03 Lanreotide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 November 2007
- Identifiers
- RxCUI 749811, 749813, 749814 +3DailyMed set ID 6e4a41fd-a753-4362-87ee-8cc56ed3660dNDC 15054-1060Application NDA022074
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 1 syringe in 1 pouch / .2 mL in 1 syringe | 15054-1060-4 | Ipsen Biopharmaceuticals | 1 September 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 August 2007 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lanreotide 60 mg/0.2 mL injection.
Other strengths and forms of Lanreotide
Clinical summary
Lanreotide is a somatostatin analog indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy, among other approved uses. MedsAcross supplies Lanreotide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LanreotideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SOMATULINE DEPOT prescribing information (Ipsen Biopharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Somatuline Depot 60 mg/0.2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.